Radiotherapy plus cetuximab for locally advanced squamous cell head and neck cancer in patients with cisplatin-ineligible renal dysfunction: A retrospective study.
cetuximab
comorbidity
head and neck cancer
prognostic risk factors
radiotherapy
renal dysfunction
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
14
12
2021
accepted:
22
02
2022
entrez:
15
7
2022
pubmed:
16
7
2022
medline:
16
7
2022
Statut:
ppublish
Résumé
Clinical trials have not fully demonstrated the efficacy and safety of radiotherapy plus cetuximab for locally advanced squamous cell head and neck cancer (LA-SCCHN) in patients with cisplatin-ineligible renal dysfunction. Patients who received radiotherapy plus cetuximab for LA-SCCHN at Chiba University Hospital (Chiba, Japan) between July 2013 and October 2018 were retrospectively reviewed. Background characteristics and locoregional control and overall survival rates were compared between patients with and without renal dysfunction. Survival was examined using Kaplan-Meier analysis and an adjusted Cox proportional hazards model. Kaplan-Meier analysis demonstrated that overall survival was shorter in patients with creatinine clearance of <45 ml/min (P=0.041; log-rank test). However, there was no difference in the locoregional control rate (P=0.477; log-rank test). Adjusted Cox analysis revealed that the risk of death was increased by 2.52-fold (hazard ratio, 2.52; 95% confidence interval, 1.01-6.30; P=0.048) if creatinine clearance was <45 ml/min. Moderate to severe renal dysfunction did not affect the locoregional control rate in patients with LA-SCCHN treated with radiotherapy plus cetuximab but was an adverse prognostic factor.
Identifiants
pubmed: 35836484
doi: 10.3892/ol.2022.13271
pii: OL-23-05-13271
pmc: PMC9258593
doi:
Types de publication
Journal Article
Langues
eng
Pagination
152Informations de copyright
Copyright: © Imai et al.
Déclaration de conflit d'intérêts
TY reports grants and personal fees from Merck Chemicals, during the study period; and grants and personal fees from Eli Lilly, grants and personal fees from Ono Pharmaceutical Co., grants and personal fees from Chugai Pharmaceutical Co., grants and personal fees from MSD, grants and personal fees from Takeda, grants from Daiichi Sankyo, personal fees from Novartis, grants from Kyowa-Hakko Kirin, personal fees from Boehringer Ingelheim, personal fees from AstraZeneca, and grants and personal fees from Taiho Pharmaceutical Co. outside the submitted work. The other authors declare that they have no competing interests.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Radiother Oncol. 2007 Oct;85(1):156-70
pubmed: 17482300
Adv Chronic Kidney Dis. 2018 Jan;25(1):49-56
pubmed: 29499887
J Clin Oncol. 2013 Mar 1;31(7):845-52
pubmed: 23182993
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Protein Cell. 2018 Jan;9(1):15-32
pubmed: 28421387
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
J Clin Oncol. 2004 Jan 1;22(1):69-76
pubmed: 14657228
Crit Rev Oncol Hematol. 2017 Dec;120:98-110
pubmed: 29198343
J Clin Oncol. 2016 Feb 10;34(5):427-35
pubmed: 26644536
Head Neck. 2019 Apr;41(4):E55-E58
pubmed: 30614125
Cancer Chemother Pharmacol. 2014 Jun;73(6):1303-6
pubmed: 24705976
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544
Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):427-33
pubmed: 11173137
Int J Cancer. 2007 Oct 15;121(8):1813-20
pubmed: 17546592
N Engl J Med. 1998 Jun 18;338(25):1798-804
pubmed: 9632446
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):915-22
pubmed: 20947269
Head Neck. 2015 Mar;37(3):386-92
pubmed: 24431011
Head Neck. 2009 Dec;31(12):1647-50
pubmed: 19283845
Cancer. 2019 Feb 1;125(3):406-415
pubmed: 30341983
Front Oncol. 2019 Feb 21;9:86
pubmed: 30847300
Clin Cancer Res. 2000 Feb;6(2):701-8
pubmed: 10690556
Lancet Oncol. 2012 Feb;13(2):145-53
pubmed: 22261362
J Clin Pharmacol. 2008 Mar;48(3):267-78
pubmed: 18218786
Ann Surg Oncol. 2007 Apr;14(4):1449-57
pubmed: 17235712
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
Lancet Oncol. 2010 Jan;11(1):21-8
pubmed: 19897418
N Engl J Med. 2003 Nov 27;349(22):2091-8
pubmed: 14645636
J Clin Oncol. 2007 Jun 1;25(16):2191-7
pubmed: 17538164
Clin Cancer Res. 2000 Jun;6(6):2166-74
pubmed: 10873065
Support Care Cancer. 2021 Jul;29(7):3497-3506
pubmed: 33150521
Cancer Treat Rev. 1995 Jan;21(1):33-64
pubmed: 7859226
Int J Dermatol. 2017 Jun;56(6):602-609
pubmed: 28247918
Oral Oncol. 2014 Nov;50(11):1041-8
pubmed: 25176576
Eur J Cancer. 2007 Jan;43(1):35-45
pubmed: 17098420
J Clin Oncol. 2003 Jan 1;21(1):92-8
pubmed: 12506176
Eur J Cancer. 2016 Nov;67:174-182
pubmed: 27669504
Lancet. 2019 Jan 5;393(10166):51-60
pubmed: 30449623
Head Neck. 2016 Oct;38(10):1495-500
pubmed: 27044005
Ann Oncol. 2020 Nov;31(11):1462-1475
pubmed: 33239190
Cancer. 2018 Dec 1;124(23):4486-4494
pubmed: 30332498
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902
BioDrugs. 2011 Apr 1;25(2):129-33
pubmed: 21443275
Am J Clin Oncol. 2016 Feb;39(1):27-31
pubmed: 24401670